Translate
About
Eupraxia Pharmaceuticals Inc (TO:EPRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Apr 21 2026
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis 
Apr 13 2026
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 17 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Mar 13 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Recent Videos
“Turning EOE Into a Once-A-Year Appointment" w/ Eupraxia (NASDAQ: EPRX) CEO James A. Helliwell M.D.
Apr 01, 2026
Eupraxia Pharma: My View on Their Growth & Dilution Risks
Mar 13, 2026
How New Drug Delivery Methods Are Changing Lives: Eupraxia’s Innovations Explained -James Helliwell
Oct 14, 2025
Investing in Tomorrow's Giants: Palantir, AppLovin, Carvana, and Eupraxia Pharmaceuticals
Sep 23, 2025
Financials
Revenue
CA$0
Market Cap
CA$611.96 M
EPS
-1.43